Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells

[1]  François G. Meyer,et al.  Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.

[2]  M. Holzenberger,et al.  Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. , 2008, Cancer research.

[3]  Ina Prade,et al.  Wild‐type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  P. Nelson,et al.  An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer , 2007, Clinical Cancer Research.

[5]  H. Werner,et al.  A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. , 2007, Cancer letters.

[6]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[7]  P. Nelson,et al.  Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors , 2006, Clinical Cancer Research.

[8]  P. Nelson,et al.  Interaction of IGF signaling and the androgen receptor in prostate cancer progression , 2006, Journal of cellular biochemistry.

[9]  H. Werner,et al.  The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action , 2006, Trends in Endocrinology & Metabolism.

[10]  S. Srivastava,et al.  Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival , 2006, Oncogene.

[11]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[13]  C. Roberts,et al.  Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. , 2005, Cancer research.

[14]  Michael Ittmann,et al.  Mutation of the androgen receptor causes oncogenic transformation of the prostate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Plymate,et al.  Androgen receptor (AR) expression in AR‐negative prostate cancer cells results in differential effects of DHT and IGF‐I on proliferation and AR activity between localized and metastatic tumors , 2004, The Prostate.

[16]  S. Friedman,et al.  Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. , 2004, Endocrinology.

[17]  J. Bourhis,et al.  Environmental, genetic, and molecular features of prostate cancer. , 2004, The Lancet. Oncology.

[18]  C. Chang,et al.  Recent advances in androgen receptor action , 2003, Cellular and Molecular Life Sciences CMLS.

[19]  R. Vessella,et al.  LuCaP 35: A new model of prostate cancer progression to androgen independence , 2003, The Prostate.

[20]  E. Bissonette,et al.  Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.

[21]  F. Orio,et al.  Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines , 2002, Molecular and Cellular Endocrinology.

[22]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Vessella,et al.  Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells , 2002, The Prostate.

[24]  R. Poulsom,et al.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.

[25]  Liang Xia,et al.  Functional analysis of 44 mutant androgen receptors from human prostate cancer. , 2002, Cancer research.

[26]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[27]  C. Sawyers,et al.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). , 2001, Cancer research.

[28]  P. Nelson,et al.  A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. , 2001, Cancer research.

[29]  S. Yeh,et al.  Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[31]  J. Jorcano,et al.  Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Bubley,et al.  Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. , 1999, The American journal of pathology.

[33]  J. Kopchick,et al.  Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. , 1999, Endocrinology.

[34]  B. Foster,et al.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. , 1999, Cancer research.

[35]  S. Maygarden,et al.  Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line , 1998, The Prostate.

[36]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[37]  S. Plymate,et al.  Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. , 1997, Endocrinology.

[38]  J. Thrasher,et al.  The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. , 1996, The Journal of clinical endocrinology and metabolism.

[39]  Barrack Er.  Androgen receptor mutations in prostate cancer. , 1996 .

[40]  J. Thrasher,et al.  Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. , 1996, The Journal of clinical endocrinology and metabolism.

[41]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[42]  C. Jackson-Cook,et al.  Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: Association with decreased epidermal growth factor receptor (EGFR) expression , 1994, International journal of cancer.

[43]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[44]  F. Schröder,et al.  Endocrine therapy for prostate cancer: recent developments and current status. , 1993, British journal of urology.

[45]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[46]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[47]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[48]  S. Plymate,et al.  Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. , 2001, Endocrinology.

[49]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. , 1994, Cancer research.

[50]  H. Werner,et al.  Molecular and cellular aspects of insulin-like growth factor action. , 1994, Vitamins and hormones.

[51]  M. Waters,et al.  of Insulin-Like Growth , 1993 .